Physician profile
Danny P Malone
NPI 1497830434
$6,864.57
in general payments reported to CMS, 2019-2025
27 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 88% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $436 · 2021: $1,186 · 2022: $1,556 · 2023: $1,078 · 2024: $293 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436 · Entertainment: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.96 |
| Entertainment | $126.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,930.22 | 2022-2025 | Infuse, Ultra Multifocal Toric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,459.31 | 2019-2021 | |
| Alcon Vision LLC | $914.99 | 2019-2025 | Total30, Precision7, Precision 1 |
| Coopervision INC. | $844.74 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Biotissue Holdings INC. | $294.69 | 2021-2025 | |
| Oculus, INC. | $235.09 | 2019 | |
| Abb Con-Cise Optical Group LLC | $198.27 | 2022 | |
| Optos, INC. | $126.73 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $124.25 | 2021 | |
| Genzyme Corporation | $122.03 | 2019 | |
| Abbvie INC. | $106.27 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $54.39 | 2023-2025 | Acuvue |
| Dompe US, INC. | $49.33 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $45.52 | 2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $33.64 | 2019-2020 | |
| Sight Sciences, INC. | $33.57 | 2020 | |
| Visioneering Technologies, INC. | $22.08 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $21.20 | 2019 | |
| Oyster Point Pharma, INC. | $18.98 | 2023 | Tyrvaya |
| Allergan, INC. | $18.02 | 2022 | |
| Thea Pharma INC. | $17.88 | 2025 | Iyuzeh |
| Novo Nordisk INC | $17.31 | 2023 | Wegovy, Saxenda |
| Lumenis, INC | $14.89 | 2021 | |
| Astellas Pharma US INC | $14.63 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $12.87 | 2020 | |
| Quidel Corporation | $8.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.